

June 6, 2023

Kidwell Bio Corporation

Code: 4584 (Growth Market, TSE)

Masaharu Tani, President & CEO

Announcement of organizational and personnel changes

Tokyo, June 6, 2023 –Based on the announcement of appointment of New CEO and Board Directors today, the following organizational and personnel changes will be made subject to resolution on the election of director candidates to be submitted at the 23rd ordinary general meeting of shareholders to be held on June 29, 2023.

1. About organizational changes


(1) Reasons for the organizational changes

Kidwell Bio Corporation (hereafter KWB) will renew its management structure to maximize KWB's corporate value while further accelerating the growth strategies.

(2) Reorganization of organizational structure

Name of Div.	Changes	Main duties
Research & Development Div.	Functional partitioning of current Research & Development Div.	Basic research and exploratory research, etc.
Development Div.	Functional partitioning of current Research & Development Div.	Clinical development of development products and manufacturing development etc.
Corporate Administration Div.	Operational changes of current Business Administration Div.	Budget & Control, accounting, HR and general affairs
CEO Office	New	Corporate planning, business development, PR & IR and legal Affairs

(3) New organizational structure



2. About personnel changes

Name	New title	Current title
Shinya Kurebayashi	Board Director President & CEO Corporate Officer Chief Communication Officer	Corporate Officer Chief Business Officer
Masayuki Kawakami	Board Director Corporate Officer Chief Operating Officer (COO) Chief Development Officer (CDO)	Corporate Officer Chief Operating Officer
Yasuyuki Mitani	Corporate Officer Chief Scientific Officer (CSO)	Director, Business Development Dept., Business Development Div.
Munehika Sakabe	Corporate Officer Chief Manufacturing Officer (CMfo)	Director, Development Dept., Research & Development Div.
Yasuo Sakae	Chief Administration Officer (CAO)	Corporate Officer Chief Financial Officer
Shinya Yano	Head of Quality Assurance Office	Deputy Head of Portfolio Strategy & Product Planning Office
Takahiro Kurihara	Head of CEO Office	Manager, Corporate Planning Dept., Business Administration Div.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com